OmniAb, Inc. is a pharmaceutical company based in the United States that specializes in therapeutic antibody discovery technologies. With an ESG score of 36.5 and a high-risk assessment, OmniAb is at the forefront of drug discovery technology. Their innovative platform utilizes transgenic animals like OmniRat, OmniMouse, and OmniChicken to efficiently discover high-quality, fully human antibodies for various diseases. The company's focus on environment, sustainability, and governance sets them apart in the industry.